Literature DB >> 18677148

Symptoms of menopause: hot flushes.

Nanette Santoro1.   

Abstract

Vasomotor symptoms (VMSs) are highly prevalent during the peri- and early postmenopause. They constitute a major driver for patient self-referral for medical care. Although most women will experience an abatement of their VMS by 5 years after their final menses, women with early or surgical menopause may have worse or more persistent symptoms, and up to 16% of naturally menopausal women continue to experience VMS well after their menopause is past. Although estrogen is the most effective known therapy, it is neither appropriate nor desirable for every symptomatic woman, and nonhormonal treatments such as gabapentin, selective serotonin reuptake inhibitors/selective norepinephrine reuptake inhibitors drugs, and the antihypertensives clonidine and alphamethyldopa may be helpful for some women. There is mounting evidence to support the ineffectiveness of many proposed complementary and alternative modalities. This review will highlight the natural history of VMS and the current medical evidence supporting various treatments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18677148     DOI: 10.1097/GRF.0b013e31818093f6

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  18 in total

Review 1.  Sex, hormones and neuroeffector mechanisms.

Authors:  E C Hart; N Charkoudian; V M Miller
Journal:  Acta Physiol (Oxf)       Date:  2010-11-09       Impact factor: 6.311

Review 2.  Perimenopause as a neurological transition state.

Authors:  Roberta D Brinton; Jia Yao; Fei Yin; Wendy J Mack; Enrique Cadenas
Journal:  Nat Rev Endocrinol       Date:  2015-05-26       Impact factor: 43.330

3.  Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms.

Authors:  Dale W Stovall; Kirby Tanner-Kurtz; JoAnn V Pinkerton
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

4.  Ambient temperature and 17β-estradiol modify Fos immunoreactivity in the median preoptic nucleus, a putative regulator of skin vasomotion.

Authors:  Penny A Dacks; Sally J Krajewski; Naomi E Rance
Journal:  Endocrinology       Date:  2011-04-26       Impact factor: 4.736

5.  Neurokinin 3 Receptor-Expressing Neurons in the Median Preoptic Nucleus Modulate Heat-Dissipation Effectors in the Female Rat.

Authors:  Melinda A Mittelman-Smith; Sally J Krajewski-Hall; Nathaniel T McMullen; Naomi E Rance
Journal:  Endocrinology       Date:  2015-03-31       Impact factor: 4.736

6.  The soy isoflavones for reducing bone loss (SIRBL) study: a 3-y randomized controlled trial in postmenopausal women.

Authors:  D Lee Alekel; Marta D Van Loan; Kenneth J Koehler; Laura N Hanson; Jeanne W Stewart; Kathy B Hanson; Mindy S Kurzer; C Theodore Peterson
Journal:  Am J Clin Nutr       Date:  2009-11-11       Impact factor: 7.045

7.  Effects of estradiol on the thermoneutral zone and core temperature in ovariectomized rats.

Authors:  Penny A Dacks; Naomi E Rance
Journal:  Endocrinology       Date:  2010-01-05       Impact factor: 4.736

8.  Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature.

Authors:  Melinda A Mittelman-Smith; Hemalini Williams; Sally J Krajewski-Hall; Nathaniel T McMullen; Naomi E Rance
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

9.  Costs of hormonal and nonhormonal prescription medications for hot flashes.

Authors:  Amie Williams-Frame; Janet S Carpenter
Journal:  Womens Health (Lond)       Date:  2009-09

10.  Purification of germline stem cells from adult mammalian ovaries: a step closer towards control of the female biological clock?

Authors:  Jonathan L Tilly; Evelyn E Telfer
Journal:  Mol Hum Reprod       Date:  2009-06-09       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.